Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-22
2011-03-22
Cordero Garcia, Marcela M (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S200000, C548S953000
Reexamination Certificate
active
07910609
ABSTRACT:
Novel compounds inhibiting the integrin α2β1/GPIa-IIa receptor are disclosed. Also disclosed are pharmaceutical compositions containing the compounds, as well as methods of their therapeutic use. The compounds disclosed are useful, inter alia, as inhibitors of integrin α2β1/GPIa-IIa-mediated activity.
REFERENCES:
patent: 6096707 (2000-08-01), Heino et al.
patent: 6369034 (2002-04-01), Doherty et al.
patent: 6423688 (2002-07-01), Thorsett et al.
patent: 6645939 (2003-11-01), Durette et al.
patent: 6734311 (2004-05-01), Hagmann et al.
patent: 6900179 (2005-05-01), Thorsett et al.
patent: 6943180 (2005-09-01), Doherty et al.
patent: 2003/0100585 (2003-05-01), Duplantier et al.
patent: 2004/0072850 (2004-04-01), Knegtel et al.
patent: WO 03/008380 (2003-01-01), None
patent: WO 2006/133338 (2006-12-01), None
patent: WO 2007/027742 (2007-03-01), None
Ettmayer et al. Lessons Learned from Marketed and Investigational Prodrugs. J Med Chem 2004, vol. 47, No. 10, pp. 2393-2404.
Han et al. Targeted Prodrug Design to Optimize Drug Delivery. AAPS Pharmsci 2000. vol. 2, No. 1, article 6, p. 1.
Testa. Prodrug research: futile or fertile? biochem Pharmacol. 2004, vol. 68, pp. 2097-2106.
Vippagunta et al. Crystalline solids. Adv. Drug Delivery Reviews. 2001, vol. 48, pp. 3-26.
Baronas-Lowell D, Lauer-Fields JL, Borgia JA, Sferrazza GF, Al-Ghoul M, Minond D, Fields GB. Differential Modulation of Human Melanoma Cell Metalloproteinase Expression by Alpha2Beta1 Integrin and CD44 Triple-Helical Ligands Derived from Type IV Collagen. J Biol Chem. 279(42), 43503-13, 2004.
Bellavite, P. A., G.; Guzzo, P.; Arigliano, P.; Chirumbolo, S.; Manzato, F.; Santonastaso, C. A Colorimetric Method for the Measure of Platelet Adhesion in Microtiter Plates. Anal. Biochem. 1994, 216, 444-450.
Bennett, J. S. a. V., G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J. Clin. Invest. 1979, 64, 1393-1401.
Bennett, J. S. C., C.; Vilaire, G.; Mousa, S. A.; DeGrado, W. F. Agonist-Activated alphavbeta3 on Platelets and Lymphocytes Binds to the Matrix Protein Osteopontin. J. Biol. Chem. 1997, 272, 8137-8140.
Bennett, J. S. Structure and function of the platelet integrin alphallbbeta3. J. Clin. Invest. 2005, 115, 3363-3369.
Chen et al, “EvidenceThat Ligand and Metal Ion Binding to Integrin a4b1 Are Regulated through a Coupled Equilibrium,” The Journal of Biological Chemistry, 276(39), 36520-36529.
Chen H, Kahn ML. Reciprocal signaling by integrin and nonintegrin receptors during collagen activation of platelets. Mol Cell Biol. 23(14):4764-77, 2003.
Choi, S. V., G.; Marcinkiewicz, C.; Winkler, J. D.; Bennett, J. S.; DeGrado, W. F. . Small Molecule Inhibitors of Integrin alpha2beta1. J. Med. Chem. 2007, 50, 5457-5462.
Connors, W. L. J., J.; White, D. J.; Puranen, J. S.; Kankaanpaa, P.; Upla, P.; Tulla, M.; Johnson, M. S.; Heino, J. Two synergistic activation mechanisms of integrin alpha2beta1 integrin-mediated collagen binding. J. Biol. Chem. 2007, 282, 14675-14683.
DeWood, M. A. S., J.; Notske, R.; Mouser, L. T.; Burroughs, R.; Golden, M. S.; Lang, K. T. . Prevalence of Total Coronary Occlusion During the Early Hours of Transmural Myocardial Infarction. N. Eng. J. Med. 1980, 303, 897-902.
Emsley J, Knight CG, Farndale RW, Barnes MJ, Liddington RC. Structural Basis of Collagen Recognition by Integrin Alpha2Beta1. Cell. 101(1), 47-56, 2000.
Emsley, J. K., S. L.; Bergelson, J. M.; Liddington, R. C. Crystal Structure of the I Domain from Integrin alpha2beta1. J. Biol. Chem. 1997, 273, 28512-28517.
Falk, E, Shah, P.K. & Fuster, V. Coronary Plaque Disruption. Circulation 92, 657-671 (1995).
Feire AL, Koss H, Compton T. Cellular Integrins Function as Entry Receptors For Human Cytomegalovirus Via a Highly Conserved Disintegrin-Like Domain. Proc Natl Acad Sci U S A. 101(43), 15470-5, 2004.
Ferarra, N. The Role of Vascular Endothelial Growth Factor in Pathological Angiogenesis. Breast Cancer Res Treat. 36(2), 127-37, 1995.
Folkman J. Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease. Nat Med. 1(1), 27-31, 1995.
Furihata, K. N., D. J.; Kunicki, T. J. Influence of platelet collagen receptor polymorphisms on risk for arterial thrombosis. Arch. Pathol. Lab. Med. 2002, 126, 305-309.
Fuster, V., Badimon, L., Badimon, J.J. & Chesebro, J.H. The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes (1). N. Engl. J. Med. 326, 242-250, 1992.
Graham KL, Halasz P, Tan Y, Hewish MJ, Takada Y, Mackow ER, Robinson MK, Coulson BS. Integrin-using rotaviruses bind alpha2beta1 integrin alpha2 I domain via VP4 DGE sequence and recognize alphaXbeta2 and alphaVbeta3 by using VP7 during cell entry. J Virol. 77(18), 9969-78, 2003.
Hagmann, W.K., The discovery and potential of N-sulfonylated dipeptide VLA-4 antagonists. Curr. Top Med. Chem., 2004, 4(14), 1461-1471.
Han J, Jenq W, Kefalides NA. Integrin Alpha2Beta1 Recognizes Laminin-2 and Induces C-erb B2 Tyrosine Phosphorylation in Metastatic Human Melanoma Cells. Connect Tissue Res. 40(4), 283-93, 1999.
Handa, M., ; Watanabe, K.; Kawai, Y.; Kamata, T.; Koyama, T.; Nagai, H.; Ikeda, Y. Platelet unresponsiveness to collagen: involvement of glycoprotein Ia-IIa (alpha2beta1 integrin) deficiency associated with a myeloproliferative disorder. Thromb. Haemost. 1995, 73, 521-528.
He L, Pappan LK, Grenache DG, Li Z, Tollefsen DM, Santoro SA, Zutter MM. The contributions of the alpha 2 beta 1 integrin to vascular thrombosis in vivo. Blood. 102(10):3652-7, 2003.
Holtkotter, O. N., B.; Smyth, N.; Muller, W.; Hafner, M.; Schulte, V.; Krieg, T.; Eckes, B. Integrin alpha2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen. J. Biol. Chem. 2002, 277, 10789-10794.
Huryn, D.M. et al., The identification and optimization of orally efficacious, small molecule VLA-4 antagonists. Curr. Top. Med. Chem., 2004, 4(14), 1473-1484.
Huryn, D.M. et al., Synthesis, characterization and evaluation of pro-drugs of VLA-4 antagonists. Bioorg. Med. Chem Lett., Apr. 5, 2004, 14(7), 1651-1654 Erratum in: Bioorg Med Chem Lett. Nov. 1, 2004;14(21):5449.
Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 110(6):673-87. Review, 2002.
Inoue, O. et al., Integrin alpha2beta1 mediates outside-in regulation of platelet spreading on collagent through activation of Src Kinases and PLCgamma2. J. Cell Biol. 160(5): 769-80 (2003).
Jackson SP and Schoenwaelder SM. Antiplatelet Therapy: In Search of the ‘Magic Bullet’. Nat. Rev. Drug. Discov. 2(10), 775-89, 2003.
Jung SM, Moroi M. Platelets interact with soluble and insoluble collagens through characteristically different reactions. J Biol Chem. 273(24):14827-37, 1998.
Jung, S. M. A. M., M. Signal-transducing mechanisms involved in activation of the platelet collagen receptor integrin alpha2beta1. J. Biol. Chem. 2000, 275, 8016-8026.
Kamenecka TM, Lanza T Jr, de Laszlo SE, Li B, McCauley ED, Van Riper G, Egger LA, Kidambi U, Mumford RA, Tong S, MacCoss M, Schmidt JA, Hagmann WK. N-aryl-prolyl-dipeptides as potent antagonists of VLA-4. Bioorg Med Chem Lett. Aug. 19, 2002;12(16):2205-8.
Kehrel, B. B., L.; Kokott, R.; Mesters, R.; Stenzinger, W.; Clemetson, K. J.; van der Loo, J. Deficiency of intact thrombospondin and membrane glycoprotein Ia in platelets with defective collagen-induced aggregation and spontaneous loss of disorder. Blood 1988, 71, 1074-1078.
Knight, C.G. et al., The collagen-binding A-domains of integrins alpha(1)beta(1) and alpha(2)beta(1) recognize the same specific amino acid sequence, GFOGER, in native (triple-helical) collagens. J. Biol. Chem., 2000, 275, 35-40.
Knutson JR, Iida J, Fields GB, McCarthy JB. CD44/Chondroitin Sulfate Proteoglycan and Alpha 2 Beta 1 Integrin Mediate Human Melanoma Cell Migration on Type IV Collagen and Invasion of Basement Membranes. Mol Biol Cell. 7(3), 383-96, 1996.
Koo, G.C. et al., A small molecule very late antigen-4 antagonist can inhibit ovalbumin-induced lung inflammation. Am. J. Respir. Crit. Care Med., May 15, 2003, 167(10), 1400-1409.
Kritzik M, Savage B, Nugent
Basra Sandeep
Bennett Joel S.
Choi Sung-wook
DeGrado William F.
Miller Meredith W.
Cordero Garcia Marcela M
The Trustees of the University of Pennsylvania
Woodcock & Washburn LLP
LandOfFree
Inhibitors of integrin alpha2beta1 with modified urea moiety does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of integrin alpha2beta1 with modified urea moiety, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of integrin alpha2beta1 with modified urea moiety will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2699148